Conference Day Two
8:00 am Morning Coffee
Improving Clarity & Synchronization of Efforts for Successful Development & Commercialization of TILs
8:30 am Panel Discussion: Key Considerations for Increasing TIL Treatment Capacity & Preparing for Commercialization
Synopsis
- What are key steps to increase TIL infrastructure and meet patient demand?
- Considerations such as TIL treatment facilities, staff recruitment and training, and resources
- What are the model regulatory and reimbursement strategies for TILs?
- Navigating the current regulatory landscape and discussing key considerations when preparing for commercialization
9:15 am Key Qualities of TILs & Hallmarks of Successfully Developing TIL Therapies
Synopsis
- Highlighting advantages of TIL poly-clonality and state-of-the-art approaches such as AI/ML to obtain and preserve truly tumor reactive T-cells
- Identifying gene-modifications to enhance TIL expansion, persistence, and efficacy
- Discussing current innovations in cell culture methods for effective TIL expansion
9:45 am Presentation By Biosharing Network
Synopsis
10:15 am Morning Refreshment Break & Networking
Preclinical & Translation
Equipping TILs with Necessary Modifications to Persist in Immunosuppressive Tumor Microenvironments
11:00 am Rejuvenation of T-Cells Results in Younger Epigenetic Age & Improved Anti-Tumor Functions In Vitro & In Vivo
Synopsis
- Novel potential disruptive technology to rejuvenate T-cells across multiple therapeutic modalities
- Rejuvenated T-cells show younger epigenetic age, enhanced cell proliferation and cytokine release, and sustained antitumor activity in vitro and in vivo
- Rejuvenated TILs preserve polyclonal anti-tumor TCR repertoire and display improved antitumor properties
11:30 am Utilizing CoSTAR Cells for Persistent Activity in the Tumor Microenvironment
Synopsis
- Tumor reactive T-cells become dysfunctional within the tumor microenvironment (TME), where little co-stimulation is present
- Provision of co-stimulation in the TME by genetic modification of TIL with CoStAR® restores T-cell function in vitro and improves anti-tumor efficacy in pre-clinical models
12:00 pm Counteracting T-Cell Exhaustion: T-Cell Therapy Meets Organelle Medicine
Synopsis
- Bone marrow stromal cells transfer mitochondria to CD8+ T cells via intercellular nanotube connections.
- Mitochondrial transfer augments CD8+ T cell metabolic fitness
- Mitochondrial transfer empowers TCR and CAR-modified T cells as well as TILs to counteract exhaustion and fight tumors more effectively.
Clinical Strategy & Manufacturing
Advancing Sample Collection Methods to Set Manufacturing Up for Success
11:00 am Optimizing Starting Material Quality through Targeted Sample Collection
Synopsis
- What are some approaches we can take to increase the proportion of tumor reactive T-cells in starting material?
- Exploring imaging techniques to identify biologically and clinically relevant tumor areas as a starting material for TIL
- Determining the quality of antigen-specific T-cell responses associated with the original location in the starting tissue material
11:30 am Circulating Tumor Reactive T-Cells (cTRLs) – Characteristics & Novel Approach to Isolation
Synopsis
- Utilizing IsoQore technology for effective isolation of cTRLs from blood as a means of non-invasive sample collection
- Key characteristics and advantages of cTRLs
Harvesting the Wealth of TILs: Navigating the Commercial Landscape
12:00 pm From Bedside to Bankside: Exploring the Commercial Potential of TIL as a Therapeutic Pillar
Synopsis
- Commercial positioning of TIL in I/O
- Key strategies to ensure TILs are commercially viable for developers
- Opportunities for biotech companies to leverage their technology for licensing
12:30 pm Lunch Break & Networking
1:30 pm Reverting TIL Exhaustion to Generate a TIL Product with More Stemness-Like T-Cells & a Broader T-Cell Repertoire to Improve Clinical Outcome
Synopsis
- Mapping T-cell specificities against tumor associated and HPV-derived antigens in TIL therapy products in cervical cancer
- Key strategies for ex vivo enrichment of tumor-reactive TILs including reinvigorating exhausted TILs and selective expansion
- Arming T-cells against oxidative stress preserving killing functionality in the hostile tumor microenvironment
2:00 pm The Discovery & Development of Next-Generation Long-Lasting Anti-Exhaustion TIL Therapies
Synopsis
- Design and development of function and persistence enhanced GT2 series TIL products engineered by StaViral® virus platform
- Development of GT3 series TIL products by CRISPR KO of potent immunoregulatory targets identified through ImmuT Finder®, a genome-wide CRISPR/Cas9 screening platform
- Preliminary safety and efficacy of next-gen TIL products in human trial as monotherapy in advanced solid tumors
Understanding of Adverse Events for Improved Patient Treatment & Clinical Retention
1:30 pm Patient Selection & Adverse Event Management for Solid Tumor TIL Therapy
Synopsis
- Criteria for appropriate patient selection
- Considerations for bridging therapy
- Identification and management of treatment-related adverse events
2:00 pm Panel Discussion: Evaluating Current Treatment Procedures to Identify Gaps & Opportunities in Treatment Protocols
Synopsis
- Evaluating the need for lymphodepletion and other pre-treatment protocols
- How do we determine timing and order of treatment procedures when prioritizing the patient?
- How do treatment protocols differ between different patients?
2:30 pm Afternoon Break & Refreshments
Boosting Understanding of TIL & Solid Tumor Mechanisms to Develop an Effective TIL Product
3:30 pm Optimizing Different Cell Populations for an Effective TIL Product
Synopsis
- Evaluating important differences between cell types such as CD4+ and CD8+ T-cells for a well-rounded TIL effective product
- How can we select different cell types and ensure consistent long-term maintenance and proliferation
- What is the role of dendritic cells in TIL Therapy products?
4:00 pm Exploring the Characteristics of Gamma Delta TIL to Treat Patients with Solid Tumors
Synopsis
- Epithelial normally serve as mucosal barriers, sites for selective transport and harbor immune cells including gamma delta T-cells
- Gamma delta T-cells diminish with age, coincident with increased epithelial tumor cells
- Gamma delta TIL specifically recognize autologous tumor equivalent or better than alpha beta TIL
4:30 pm Understanding of TIL Mechanisms for Successful Targeting of Potent T-Cells
Synopsis
- Understanding the tumor microenvironment of origin that impacts the quality of T-cell product
- Understanding the molecular ingredients of TIL product potency
- Understanding the state dynamics of T-cells upon expansion and transfer
- Enhancing TIL product potency by selectively enriching for tumor specific T-cells